Physician profile
Bridget Herring
NPI 1265124192
$1,332.35
in general payments reported to CMS, 2019-2025
13 companies · $95.27 in 2025
The $95.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $245 · 2024: $992 · 2025: $95.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $279.03 | 2023-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $191.62 | 2023-2025 | Farxiga, Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $176.60 | 2023-2024 | |
| Scpharmaceuticals INC. | $120.76 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.44 | 2023-2024 | Jardiance |
| Pfizer INC. | $91.58 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $89.50 | 2023-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $78.19 | 2023-2024 | Xarelto |
| United Therapeutics Corporation | $77.66 | 2023-2025 | Tyvaso, Tyvaso |
| Cvrx, INC. | $68.53 | 2024-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $21.10 | 2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.69 | 2024 | Lifevest |
| Abiomed | $17.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.